These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3897595)

  • 1. Using end-stage renal disease facility surveys to monitor end-stage renal disease program trends. The Data Committee of the National Forum of End-Stage Renal Disease Networks.
    JAMA; 1985 Oct; 254(13):1776-80. PubMed ID: 3897595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network.
    Brown J; Josephson M
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis utilization in the Toronto region from 1981 to 1992. Toronto Region Dialysis Committee.
    Mendelssohn DC; Chery A
    CMAJ; 1994 Apr; 150(7):1099-105. PubMed ID: 8137190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual facility survey of providers of ESRD therapy. USRDS. United States Renal Data System.
    Am J Kidney Dis; 1997 Aug; 30(2 Suppl 1):S178-86. PubMed ID: 9259701
    [No Abstract]   [Full Text] [Related]  

  • 5. The American health care system. The End Stage Renal Disease Program.
    Iglehart JK
    N Engl J Med; 1993 Feb; 328(5):366-71. PubMed ID: 8419833
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation.
    Garg PP; Frick KD; Diener-West M; Powe NR
    N Engl J Med; 1999 Nov; 341(22):1653-60. PubMed ID: 10572154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Freestanding Dialysis Facility Quality Incentive Program Scores and Mortality Among Incident Dialysis Patients in the United States.
    Ajmal F; Probst JC; Brooks JM; Hardin JW; Qureshi Z; Jafar TH
    Am J Kidney Dis; 2020 Feb; 75(2):177-186. PubMed ID: 31685294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities.
    Griffiths RI; Powe NR; Gaskin DJ; Anderson GF; de Lissovoy GV; Whelton PK
    Health Serv Res; 1994 Oct; 29(4):473-87. PubMed ID: 7928373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis.
    Mehrotra R; Marsh D; Vonesh E; Peters V; Nissenson A
    Kidney Int; 2005 Jul; 68(1):378-90. PubMed ID: 15954930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The end-stage renal disease program: trends over the past 18 years.
    Port FK
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):3-7. PubMed ID: 1626554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health surveillance in the dialysis setting: opportunities and challenges for using electronic health records.
    Wise ME; Lovell C
    Semin Dial; 2013; 26(4):399-406. PubMed ID: 23721477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can dialysis therapy be improved? A report from the ESRD Core Indicators Project.
    McClellan WM; Frankenfield DL; Frederick PR; Flanders WD; Alfaro-Correa A; Rocco M; Helgerson SD
    Am J Kidney Dis; 1999 Dec; 34(6):1075-82. PubMed ID: 10585317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal failure services.
    McCarthy M
    Health Serv Manage; 1988 Jun; 84(3):17-9. PubMed ID: 10302548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
    Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
    G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Medicare reimbursement for end-stage renal disease: 1974-1979.
    Eggers PW
    Health Care Financ Rev; 1984; 6(1):31-8. PubMed ID: 10310848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Substitutes for renal function. Technical trends and logistics of treatment].
    Legrain M; Rottembourg J
    C R Seances Soc Biol Fil; 1981; 175(5):669-93. PubMed ID: 6456794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health policy report. Funding the End-Stage Renal-Disease Program.
    Iglehart JK
    N Engl J Med; 1982 Feb; 306(8):492-6. PubMed ID: 7035954
    [No Abstract]   [Full Text] [Related]  

  • 19. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The legislative and regulatory process in the end-stage renal disease (ESRD) program, 1973 through 1997.
    Hull AR
    Semin Nephrol; 1997 May; 17(3):160-9. PubMed ID: 9165645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.